key: cord-1033281-x924tb4t authors: Wang, Zijun; Muecksch, Frauke; Schaefer-Babajew, Dennis; Finkin, Shlomo; Viant, Charlotte; Gaebler, Christian; Barnes, Christopher; Cipolla, Melissa; Ramos, Victor; Oliveira, Thiago Y.; Cho, Alice; Schmidt, Fabian; da Silva, Justin; Bednarski, Eva; Daga, Mridushi; Turroja, Martina; Millard, Katrina G.; Jankovic, Mila; Gazumyan, Anna; Bieniasz, Paul D.; Caskey, Marina; Hatziioannou, Theodora; Nussenzweig, Michel C. title: Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection date: 2021-05-09 journal: bioRxiv DOI: 10.1101/2021.05.07.443175 sha: 6506db7abfdde39adf066e9faf28eff4c654d790 doc_id: 1033281 cord_uid: x924tb4t Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains difficult to control despite the availability of several excellent vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies1,2. Here we report on a cohort of 63 COVID-19-convalescent individuals assessed at 1.3, 6.2 and 12 months after infection, 41% of whom also received mRNA vaccines3,4. In the absence of vaccination antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable from 6 to 12 months. Vaccination increases all components of the humoral response, and as expected, results in serum neutralizing activities against variants of concern that are comparable to or greater than neutralizing activity against the original Wuhan Hu-1 achieved by vaccination of naïve individuals2,5–8. The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover, and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in variants of concern4,9. In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand dramatically after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants. Should memory responses evolve in a similar manner in vaccinated individuals, additional appropriately timed boosting with available vaccines could cover most circulating variants of concern. newly arising clones at the 12-month time point in vaccinated individuals (Extended Data Fig 138 5c ). Moreover, phylogenetic analysis revealed that sequences found at 6 and 12 months were 139 intermingled and similarly distant from their unmutated common ancestors (Extended Data Fig 140 6 ). We conclude that clonal re-expansion of memory cells in response to vaccination is not 141 associated with additional accumulation of large numbers of somatic mutations as might be 142 expected if the clones were re-entering and proliferating in germinal centers. 143 144 To determine whether the antibodies obtained from memory B cells 12 months after infection 146 bind to RBD we performed ELISAs (Fig.3a ). 174 antibodies were tested by ELISA including: 1. 147 53 that were randomly selected from those that appeared only once and only after 1 year; 2. 91 148 that appeared as expanded clones or singlets at more than one time point; 3. 30 representatives of 149 To determine whether the loss of non-neutralizing antibodies over time was due to preferential 174 loss of antibodies targeting specific epitopes, we performed BLI experiments in which a 175 preformed antibody-RBD complex was exposed to a second monoclonal targeting one of 3 176 classes of structurally defined epitopes 3,20 (see schematic in Fig. 4a ). We assayed 60 randomly 177 selected antibodies with comparable neutralizing activity from the 1.3-and 12-month time 178 points. The 60 antibodies were evenly distributed between the 2 time points and between 179 neutralizers and non-neutralizers (Fig. 4) . Antibody affinities for RBD were similar among 180 neutralizers and non-neutralizers obtained at the same time point (Fig. 4b , Extended Data Figure 181 8). Although the differences were small, both neutralizers and non-neutralizers showed increased 182 affinity over time (Fig. 4b, Extended Data Fig. 8 ). In competition experiments, all but 2 of the 183 30 non-neutralizing antibodies failed to inhibit binding of the class 1 (C105), 2 (C121 and C144) 184 or 3 (C135) antibodies tested and therefore must bind to epitopes that do not overlap with the 185 epitopes of these classes of antibodies (Fig. 4c , and Extended Data Fig. 9 ). In contrast, all but 2 186 of the 30 neutralizers blocked class 1, or 2 antibodies whose target epitopes are structural 187 components of the RBD that interact with its cellular receptor, the angiotensin-converting 188 enzyme 2 20,21 (ACE2) (Fig. 4c and Extended Data Fig. 9 ). In addition, whereas 9 of the 15 189 neutralizing antibodies obtained after 1.3 months blocked both class 1 and 2 antibodies, only 1 of 190 the 15 obtained after 12 months did so. In contrast to the earlier time point, 13 of 15 neutralizing 191 antibodies obtained after 12 months only interfered with C121, a class 2 antibody 3,20 ( Fig. 4c and 192 Extended Data Fig. 9 ). We conclude that neutralizing antibodies are retained and non-193 neutralizing antibodies targeting RBD surfaces that do not interact with ACE2 are removed from 194 the repertoire over time. 195 196 To determine whether there was an increase in neutralization breadth over time, the neutralizing 197 activity of the 60 antibodies was assayed against a panel of RBD mutants covering residues 198 associated with circulating variants of concern: R346S, K417N, N440K, A475V, E484K and 199 N501Y ( Fig. 4d The increase in breadth and overall potency of memory B cell antibodies could be due to shifts in 204 the repertoire, clonal evolution, or both. To determine whether changes in specific clones are 205 associated with increases in affinity and breadth, we measured the relative affinity and 206 neutralizing breadth of pairs of antibodies expressed by expanded clones of B cells that were 207 maintained in the repertoire over the entire observation period 3,4 . SARS-CoV-2 neutralizing 208 activity was not significantly correlated with affinity at either time point considered 209 independently (Fig. 5a) . However, there was a significant increase in overall affinity over time 210 including in the 4 pairs of antibodies with no measurable neutralizing activity (Fig 5b and 211 Supplementary (Fig. 5c ). In contrast, 10 of the 15 antibodies obtained from the same clones after 219 12 months neutralized all variants tested with IC50s as low as 1 ng/ml against the triple mutant 220 convalescents against variants of concern 15,32,33 . 242 Less is known about selection and maintenance of the memory B cell compartment. SARS-CoV-244 2 infection produces a memory compartment that continues to evolve over 12 months after 245 infection with accumulation of somatic mutations, emergence of new clones, and increasing 246 affinity all of which is consistent with long-term persistence of germinal centers. The increase in 247 activity against SARS-CoV-2 mutants parallels the increase in affinity and is consistent with the 248 finding that increasing the apparent affinity of anti-SARS-2 antibodies by dimerization or by 249 creating bi-specific antibodies also increases resistance to RBD mutations 34-37 . 250 structures over long periods of time 26 . In addition, SARS-CoV-2 protein and nucleic acid has 253 been reported in the gut for at least 2 months after infection 4 . Irrespective of the source of 254 antigen, antibody evolution favors epitopes overlapping with the ACE2 binding site on the RBD, 255 possibly because these are epitopes that are preferentially exposed on trimeric spike protein or 256 virus particles. neutralizing activity against SARS-CoV-2 variants of concern. All experiments were performed at 295 The E484K and K417N/E484K/N501Y (KEN) substitution, as well as the deletions/substitutions 453 corresponding to variants of concern were incorporated into a spike protein that also includes the 454 R683G substitution, which disrupts the furin cleaveage site and increases particle infectivity. 455 Neutralizing activity against mutant pseudoviruses were compared to a wildtype SARS-CoV-2 456 spike sequence (NC_045512), carrying R683G where appropriate. 457 SARS-CoV-2 pseudotyped particles were generated as previously described 3,10 . Briefly, 293T 458 cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV-2-SΔ19, particles were 459 harvested 48 hpt, filtered and stored at -80°C. Antibodies were identified and sequenced as described previously 3 . In brief, RNA from single 508 cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044) and 509 the cDNA stored at −20 °C or used for subsequent amplification of the variable IGH, IGL and 510 IGK genes by nested PCR and Sanger sequencing. Sequence analysis was performed using 511 MacVector. Amplicons from the first PCR reaction were used as templates for sequence-and 512 ligation-independent cloning into antibody expression vectors. Recombinant monoclonal 513 antibodies were produced and purified as previously described 3 . 514 515 Biolayer interferometry assays were performed as previously described 3 . Briefly, we used the 517 Octet Red instrument (ForteBio) at 30 °C with shaking at 1,000 r.p.m. Epitope-binding assays 518 were performed with protein A biosensor (ForteBio 18-5010), following the manufacturer's clonotypes were assigned based on their V and J genes using in-house R and Perl scripts (Fig. 540 2d). All scripts and the data used to process antibody sequences are publicly available on GitHub 541 (https://github.com/stratust/igpipeline). 542 The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 544 was compared to 131,284,220 IgH and IgL sequences generated by 45 and downloaded from 545 cAb-Rep 46 , a database of human shared BCR clonotypes available at https://cab-546 rep.c2b2.columbia.edu/. Based on the 91 distinct V genes that make up the 6902 analyzed 547 sequences from Ig repertoire of the 10 participants present in this study, we selected the IgH and 548 IgL sequences from the database that are partially coded by the same V genes and counted them 549 according to the constant region. The frequencies shown in (Extended data Fig. 4 ) are relative to 550 the source and isotype analyzed. We used the two-sided binomial test to check whether the 551 number of sequences belonging to a specific IgHV or IgLV gene in the repertoire is different Anti-IgG, IgM, IgA, IgD, CD71 and CD27 662 antibodies were used for B cell phenotype analysis Flow cytometry showing the percentage of RBD-double positive (b) K417N/E484K/N501Y mutant RBD cross-reactive (c) memory B cells from 1.3 or 6-and 12-665 months post-infection in 10 selected participants. d. as in Fig. 2c, Pie charts show the distribution 666 of antibody sequences from 4 or 12 months (lower panel). e, As in b and c. graph summarizes cell number (per 2 million B cells of immunoglobulin class of antigens binding memory B cells in samples obtained at 1.3, 6.2 and 669 12 months. f, same as in d, but summarizes percentage of CD71 positive activated antigen specific 670 B cells. Each dot is one individual. Red horizontal bars indicate mean values Graph shows comparison of 676 the frequency distributions of human V genes of anti-SARS-CoV-2 antibodies from donors at 1.3 3 , 677 6.2 4 , 12 months after infection. a, Graph shows relative abundance of human IGVH genes 678 Sequence Read Archive accession SRP010970 (green), convalescent vaccinees (blue), and 679 convalescent non-vaccinees (orange). Statistical significance was determined by two-sided 680 b and c, same as in a, but showing comparison between antibodies from donors at 681 1.3 months 3 (b), 6.2 month 4 (c), and 12 months after infection Analysis of anti-RBD antibodies. a, as in Fig. 2e, graph shows number 686 of clonally expanded B cells (per 10 million B cells) at both time points from four individuals Cells belonging the same clone are marked in the same color. Statistical significance was 688 determined using Wilcoxon matched-pairs signed rank tests. Vaccinees are marked in red IGVL (bottom) in antibodies 690 obtained after 1.3 or 6.2 or 12 months from the indicated individual. c. same as b, but graphs show 691 comparison between new clones and conserved clones in 6 vaccinated convalescent individuals at 692 12 months after infection. d. The amino acid length of the CDR3s at the IGVH and IGVL for each 693 individual Statistical significance was determined using two-tailed Mann-Whitney U-tests Evolution of anti-SARS-CoV-2 RBD antibody clone. Clonal evolution 699 of RBD-binding memory B cells from ten convalescent individuals, a, phylogenetic tree graph 700 shows clones from convalescent non-vaccinees, b, same as a Numbers refer to mutations compared to the preceding vertical node. Colors indicate timepoint orange and red represent 1.3, 6 and 12 months respectively, black dots indicate inferred 703 nodes, and size is proportional to sequence copy number Binding curves 708 (a) and EC50 dot plot (b) of mAbs isolated from non-vaccinated (black curves and dots) and from 709 vaccinated (blue curves and dots) convalescents individuals 12 months after infection. c-e, IC50 710 values of mAbs isolated 12 months c shows all 12-month antibodies irrespective of clonality, d shows singlets only, and e shows only 712 antibodies belonging to a clone or shared over time. Statistical significance was determined using 713 Geometric mean IC50 is indicated in red. f, IC50 values of shared clones of 714 mAbs cloned from B-cells from the initial 1.3-and 6.2, as well as 12-month follow-up visit, 715 divided by participant, as indicated Antibodies with IC50>1000ng/ml are plotted at 1000 ng/ml. Average IC50 values of two Biolayer interferometry affinity measurements. a-b, Graphs depict 722 affinity measurements of neutralizing (green) and non-neutralizing (red) antibodies isolated 1.3 723 months (a) or 12 months (b) after infection Extended Data Fig 3 (a) or 12 months (b) after infection were assayed for 729 competition with structurally characterized anti-RBD antibodies by biolayer interferometry 730 experiments as in Fig 4a. Graphs represent the binding of the second antibody Dotted line denotes when 1st Ab and 2nd Ab 732 are the same. For each antibody group identified in Fig 4c the left graphs represent the binding of 733 the class-representative C144 The right graphs represent the binding of the candidate antibody (2nd Ab) to 735 the complex of C144-RBD, C121-RBD, C135-RBD or C105-RBD (1st Ab) Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 757 in England mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. 759 Convergent antibody responses to SARS-CoV-2 in convalescent 761 individuals Evolution of antibody immunity to SARS-CoV-2 Distinct antibody and memory B cell responses in SARS-CoV-2 naive and 765 recovered individuals following mRNA vaccination Binding and Neutralization Antibody Titers After a Single Vaccine Dose in 768 Health Care Workers Previously Infected With SARS-CoV-2 Antibody Responses in Seropositive Persons after a Single Dose of 771 SARS-CoV-2 mRNA Vaccine Prior SARS-CoV-2 infection rescues B and T cell responses to 774 variants after first vaccine dose Development of potency, breadth and resilience to viral escape 776 mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv Measuring SARS-CoV-2 neutralizing antibody activity using 779 pseudotyped and chimeric viruses Detection of a SARS-CoV-2 variant of concern in South Africa Detection and characterization of the SARS-CoV-2 lineage B.1.526 in 783 New York. bioRxiv Exit from germinal center to become quiescent memory B cells depends 785 on metabolic reprograming and provision of a survival signal mRNA vaccination boosts cross-variant neutralizing antibodies 790 elicited by SARS-CoV-2 infection Maturation and persistence of the anti-SARS-CoV-2 memory B cell 792 response Prolonged evolution of the human B cell response to SARS-CoV-2 794 infection Potent neutralizing antibodies from COVID-19 patients define 796 multiple targets of vulnerability Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 799 from disease in a small animal model SARS-CoV-2 neutralizing antibody structures inform therapeutic 802 strategies SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 804 Blocked by a Clinically Proven Protease Inhibitor Mutational escape from the polyclonal antibody response to SARS-807 CoV-2 infection is largely shaped by a single class of antibodies. bioRxiv Escape from neutralizing antibodies by SARS-CoV-2 spike protein 810 variants Germinal Center and Extrafollicular B Cell Responses in 812 Vaccination Selection in the germinal center Generation of memory B 819 cells and their reactivation Humoral immunity. Apoptosis and 821 antigen affinity limit effector cell differentiation of a single naive B cell Generation of antibody diversity in the immune response of BALB/c 824 mice to influenza virus hemagglutinin SARS-CoV-2 natural antibody response persists up to 12 months in 827 a nationwide study from the Faroe Islands. medRxiv Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain 830 among COVID-19 convalescent plasma donors in Wuhan. bioRxiv SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in 833 humans The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused 836 neutralization, but with broader antibody binding within the RBD. bioRxiv Enhanced SARS-CoV-2 neutralization by dimeric IgA An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by 841 stabilizing inactive Spike Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape 843 in mice Multimeric nanobodies from camelid engineered mice and llamas potently 845 neutralize SARS-CoV-2 variants. bioRxiv A new coronavirus associated with human respiratory disease in China Single-step method of RNA isolation by acid guanidinium 849 thiocyanate-phenol-chloroform extraction Solid-phase reversible immobilization for 852 the isolation of PCR products Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 855 COVID-19 Disease and Unexposed Individuals A serological assay to detect SARS-CoV-2 seroconversion in humans Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal 860 Common Epitopes and Recurrent Features of Antibodies Change-O: a toolkit for analyzing large-scale B cell immunoglobulin 863 repertoire sequencing data High frequency of shared clonotypes in human B cell receptor repertoires Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody 869 Prevalence A simple method for displaying the hydropathic character of a 871 protein Amino acid side-chain partition energies and distribution of residues in 873 soluble proteins A Public Database of Memory and Naive B-Cell Receptor Sequences TranslatorX: multiple alignment of nucleotide 878 sequences guided by amino acid translations the International ImMunoGeneTics Information System. Cold 881 Spring Harb Protoc Using 883 Genotype Abundance to Improve Phylogenetic Inference The Rockefeller University has filed a provisional patent application in 577 connection with this work on which M.C.N.is an inventor (US patent 63/021,387). The patent 578 has been licensed by Rockefeller University to Bristol Meyers Squib. 579 580 Data availability statement: Data are provided in SI Tables 1-8. The raw sequencing data and 581 computer scripts associated with Figure 2 have been deposited at Github 582 (https://github.com/stratust/igpipeline). This study also uses data from "A Public Database of 583